Systemic Mastocytosis: documented pathologic response to imatinib
Russell P. Gollard,
Christine Ruemmler-Fish,
Diana Garcia,
Russell P. Gollard
Cancer & Blood Specialists of Nevada, Associated Pathologists, Henderson, Nevada, USA
Search for more papers by this authorChristine Ruemmler-Fish
Cancer & Blood Specialists of Nevada, Associated Pathologists, Henderson, Nevada, USA
Search for more papers by this authorDiana Garcia
Cancer & Blood Specialists of Nevada, Associated Pathologists, Henderson, Nevada, USA
Search for more papers by this authorRussell P. Gollard,
Christine Ruemmler-Fish,
Diana Garcia,
Russell P. Gollard
Cancer & Blood Specialists of Nevada, Associated Pathologists, Henderson, Nevada, USA
Search for more papers by this authorChristine Ruemmler-Fish
Cancer & Blood Specialists of Nevada, Associated Pathologists, Henderson, Nevada, USA
Search for more papers by this authorDiana Garcia
Cancer & Blood Specialists of Nevada, Associated Pathologists, Henderson, Nevada, USA
Search for more papers by this authorRussell P. Gollard, M.D., F.A.C.P., Cancer & Blood Specialists of Nevada, 58 N. Pecos Road, Henderson, Nevada 89074, USA.Tel: 702-822-2000; Fax: 702-938-2237; e-mail: [email protected]
No abstract is available for this article.
References
- 1 Florian S, Esterbauer H, Binder T, Mullauer L, Haas OA, Sperr WR, Sillaber C, Valent P. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1 L1/PDGFR alpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res 2006; 30: 1201–05.
- 2 Hennessy B, Giles F, Cortes J, O’brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S. Management of patients with systemic mastocytosis: review of M.D. Anderson Cancer Center experience. Am J Hematol 2004; 77: 209–14.
- 3 Pardanani A. Systemic mastocytosis: bone marrow pathology, classification, and current therapies. Acta Haematol 2005; 114: 41–51.
- 4 Tefferi A, Pardanani A. Systemic mastocytosis: current concepts and treatment advances. Curr Hematol Rep. 2004; 3: 197–202.
- 5 Tefferi A, Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 2004; 11: 58–64.
- 6 Valent P, Akin C, Sperr WR, Horny HP, Metcalfe DD. Mast cell proliferative disorders: current view on variants recognized by the World Health Organization. Hematol Oncol Clin North Am 2003; 17: 1227–41.
- 7 Valent P, Akin C, Sperr WR, et al. Mastocytosis: pathology, genetics, and current options for therapy. Leuk Lymphoma 2005; 46: 35–48.
- 8 Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, Tefferi A. Imatinib for systemic mast-cell disease. Lancet 2003; 362: 535–6.
- 9 Pardanani A, Tefferi A. Imatinib targets other than BCR-ABL and their clinical relevance in myeloid disorders. Blood 2004; 104: 1931–9.
- 10 Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003; 101: 4660–6.
- 11 Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van’t Wout JW, Verhoef G, Gerrits WB, Van Dobbenburgh OA, Pasmans SG, Fijnheer R. Cladribine therapy for systemic mastocytosis. Blood 2003; 102: 4270–6.
- 12 Pardanani A, Hoffbrand AV, Butterfield JH, Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 2004; 28: 127–31.
- 13 Tefferi A, Li CY, Butterfield JH, Hoagland HC. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 2001; 344: 307–9.
- 14 Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinase with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinase and those with regulatory-type mutations. Blood 2002; 99: 1741–4.
- 15 Gleixner KV, Mayerhofer M, Aichberger KJ, et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816 V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006; 107: 752–9.
Citing Literature
